Advances in dual- targeted therapy for HER2- positive breast cancer based on trastuzumab
-
摘要: HER-2阳性乳腺癌侵袭性强、复发率高，针对HER-2的单靶向治疗虽使患者生存期得以延长，但仍有患者发生复发转移。双靶向治疗因其作用机制不重叠，具有协同作用，使患者生存期得以进一步延长。本文以曲妥珠单抗靶向治疗为基础，对与联合抗HER-2的双靶向治疗的研究现状和进展进行综述。
-
关键词:
- 乳腺癌 /
- 人表皮生长因子受体-2 /
- 曲妥珠单抗 /
- 双靶向治疗
Abstract: Human epidermal growth factor receptor (HER)-2-positive breast cancer is a type of highly invasive breast cancer with a high recurrence rate. Although the single-targeted treatment for HER-2 prolongs survival, patients still develop recurrence and metastasis. The mechanisms of dual-targeted therapies are non-overlapping and have synergistic effects, which further improves the survival of patients. Based on trastuzumab, this article reviews the current status and progression indual-targeted therapeutic regimens containing anti-HER-2. -
表 1 HER家族相关靶向药物的主要作用机制、作用位点及不良反应
表 2 其他相关靶向药物的主要作用机制、作用位点及不良反应
-
[1] Kümler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER-2-positive breast cancer[J]. Cancer Treat Rev, 2014, 40(2):259- 270. doi: 10.1016/j.ctrv.2013.09.002 [2] Schettini F, Buono G, Cardalesi C, et al. Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going[J]. Cancer Treat Rev, 2016, 46:20-26. doi: 10.1016/j.ctrv.2016.03.012 [3] Sims AH, Zweemer AJ, Nagumo Y, et al. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer[J]. Br J Cancer, 2012, 106(11):1779-1189. doi: 10.1038/bjc.2012.176 [4] Yamashita-Kashima Y, Iijima S, Yorozu K, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER-2-positive human gastric cancer xenograft models[J]. Clin Cancer Res, 2011, 17(15):5060-5070. doi: 10.1158/1078-0432.CCR-10-2927 [5] Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER-2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9 [6] Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER- 2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA)[J]. Ann Oncol, 2013, 24(9):2278-2284. doi: 10.1093/annonc/mdt182 [7] Swain SM, Kim SB. Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER-2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double- blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2013, 14(6):461- 471. doi: 10.1016/S1470-2045(13)70130-X [8] Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER-2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER-2 and potentiates trastuzumab-dependent cell cytotoxicity[J]. Oncogene, 2009, 28(6):803-814. doi: 10.1038/onc.2008.432 [9] de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER- 2- positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response[J]. Lancet Oncol, 2014, 15(10):1137-1146. doi: 10.1016/S1470-2045(14)70320-1 [10] Carey LA, Berry DA, Cirrincione CT, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized ohase Ⅲ trial of paclitaxel plus trastuzumab with or without lapatinib[J]. J Clin Oncol, 2016, 34(6): 542-549. doi: 10.1200/JCO.2015.62.1268 [11] Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER- 2- positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(12):1183-1192. doi: 10.1016/S1470-2045(13)70411-X [12] Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2- positive breast cancer: results from the randomized phase Ⅲ adjuvant lapatinib and/or trastuzumab treatment optimization trial[J]. J Clin Oncol, 2016, 34(10):1034-1042. doi: 10.1200/JCO.2015.62.1797 [13] Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study[J]. J Clin Oncol, 2012, 30(21):2585-2592. doi: 10.1200/JCO.2011.35.6725 [14] Johnston SRD, Hegg R, Im SA, et al. Phase Ⅲ, randomized study of dual human epidermal growth factor receptor-2 (HER-2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER-2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE[J]. J Clin Oncol, 2018, 36(8):741-748. doi: 10.1200/JCO.2017.74.7824 [15] Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumabbased adjuvant therapy in HER-2-positive breast cancer (ExteNET): 5- year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9 [16] Hanusch C, Schneeweiss A, Loibl S, et al. Dual blockade with afatinib and trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy-DAFNE (GBG-70)[J]. Clin Cancer Res, 2015, 21(13):2924-2931. doi: 10.1158/1078-0432.CCR-14-2774 [17] Moulder SL, Borges VF, Baetz T, et al. Phase 1 study of ONT-380, a HER- 2 inhibitor, in patients with HER-2+ advanced solid tumors, with an expansion cohort in HER-2+ metastatic breast cancer (MBC)[J]. Clin Cancer Res, 2017, 23(14):3529-3536. doi: 10.1158/1078-0432.CCR-16-1496 [18] Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER-2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study[J]. Lancet Oncol, 2018, 19(7):880-888. doi: 10.1016/S1470-2045(18)30256-0 [19] Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER-2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2018, 19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7 [20] Wilks ST. Potential of overcoming resistance to HER-2-targeted therapies through the PI3K/Akt/mTOR pathway[J]. Breast, 2015, 24(5):548-555. doi: 10.1016/j.breast.2015.06.002 [21] Chien AJ, Cockerill A, Fancourt C, et al. A phase 1b study of the Akt-inhibitor MK- 2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER-2-amplified solid tumor malignancies[J]. Breast Cancer Res Treat, 2016, 155(3):521-530. doi: 10.1007/s10549-016-3701-7 [22] Loibl S, de la Pena, L, Nekljudova V, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER-2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase Ⅱ trial (NeoPHOEBE)[J]. Eur J Cancer, 2017, 85:133-145. doi: 10.1016/j.ejca.2017.08.020 [23] Jain S, Shah AN, Santa-Maria CA, et al. Phase Ⅰ study of alpelisib (BYL- 719) and trastuzumab emtansine (T-DM1) in HER-2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy[J]. Breast Cancer Res Treat, 2018, 171(2):371-381. doi: 10.1007%2Fs10549-018-4792-0 [24] Smith JW 2nd, Buyse ME, Rastogi P, et al. Epirubicin with cyclophos-phamide followed by docetaxel with trastuzumab and bevacizumab as neoadjuvant therapy for HER-2-positive locally advanced breast cancer or as adjuvant therapy for HER-2-positive pathologic stage Ⅲ breast cancer: a phase Ⅱ trial of the NSABP foundation research group, FB-5[J]. Clin Breast Cancer, 2017, 17(1):48-54. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b0cd6799403bb1108da531e9062e6e7f [25] Gianni L, Romieu GH, Lichinitser M, et al. AVEREL: a randomized phase Ⅲ trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER-2-positive locally recurrent/ metastatic breast cancer[J]. J Clin Oncol, 2013, 31(14):1719-1725. doi: 10.1200/JCO.2012.44.7912 [26] Gianni L, Bisagni G, Colleoni M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER- 2-positive, ER-positive breast cancer (NA-PHER-2): an exploratory, open-label, phase 2 study[J]. Lancet Oncol, 2018, 19 (2):249-256. doi: 10.1016/S1470-2045(18)30001-9 [27] Loi S, Giobbie- Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab- resistant, advanced, HER- 2- positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial [J]. Lancet Oncol, 2019, 20 (3):371-382. doi: 10.1016/S1470-2045(18)30812-X [28] Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2017, 35 (27):3105-3112. doi: 10.1200/JCO.2016.69.6179 -
点击查看大图
表(2)
计量
- 文章访问数: 125
- HTML全文浏览量: 70
- PDF下载量: 11
- 被引次数: 0
下载:
